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Abstract
Background: Extended liver resections still bear the risk of severe haemorrhage. Moreover, the amount of blood
loss during liver resection determines the need for perioperative blood transfusions and is of prognostic relevance
in oncologic surgery. Even though there is an ongoing debate about its effectiveness and tolerable duration, the
Pringle Maneuver (PM) as an occlusion of the hepatic inflow is routinely applied to reduce blood loss during
parenchymal dissection. In combination with the stapler resection technique, PM is expected to minimize blood
loss during major liver resection safely due to the short parenchymal dissection duration.
Methods: In a single center prospective, randomized, controlled, parallel, confirmatory trial the combination of PM
and stapler resection technique in patients undergoing right and left hepatectomies will be tested against the
control group that applies stapler resection without the use of PM. The primary endpoint of the study is the total
intraoperative blood loss. The measurement of the intraoperative blood loss is conducted with respect to all
handled rinse fluids during surgery and by weighing used swabs to generate accurate and comparable data.
Secondary endpoints include intra- and postoperative blood transfusion requirements, liver function parameters
and the 90-day mortality rate. A sample size of fifty-three patients in either group was calculated to detect a
clinically significant difference in blood loss of at least 450 ml with an α of 5% at 80% power. The individual
follow-up will be 90 days.
Discussion: This is the first clinical trial to test the combination of PM and stapler resection technique as a
means to reduce intraoperative blood loss in hepatic left or right resection. Given the short parenchymal
dissection duration in stapler resection, PM is expected to be applied shortly without compromising liver
function postoperatively.
Trial registration: The PriMaL StHep trial has been prospectively registered to the German Clinical Trial Registry
(WHO ID: DRKS00010427) on April 21st. 2016.
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Background
Resection is the standard treatment for a variety of be-
nign and malignant pathologies of the liver. Depending
on the size of the finding and the nature of the disease,
resections can be performed as atypical or anatomical
resections. Major liver resections, including left and
right hepatectomies and their extensions listed in the
Brisbane 2000 terminology [1], still carry the risk of se-
vere hemorrhage [2]. Perioperative blood loss (BL) not
only affects short-term outcome after surgery, it has
been shown that extensive blood loss and transfusion of
blood products are related to increased tumor recur-
rence in Hepatocellular Carcinoma (HCC) patients [3–
6]. Voogt, et al. reported the same finding in colorectal
cancer patients [7]. Accordingly, perioperative blood
transfusions in colorectal metastases resection were
found to be associated with impaired perioperative out-
come, increased recurrence rate, and reduced long term
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survival [8, 9]. Currently, it was shown that a reduction
of blood loss of 400 ml was associated with the absence
of blood transfusions in a series of 186 liver resections
[10]. Limiting intraoperative BL to avoid related blood
transfusion therefore remains mandatory in liver surgery
for malignancies; measures include resection along ana-
tomical planes, maintenance of low central venous pres-
sure (CVP), and blood saving resection techniques. Due
to the varying application of these measures and the
presence of other potential confounders, such as selec-
tion and reporting bias and uncontrolled circumstantial
effects, case series and uncontrolled studies can only re-
veal limited understanding of strategies to successfully
reduce the blood loss in major liver resections. There-
fore, this single center Randomized Controlled Trial
(RCT) which applies a highly standardized surgical tech-
nique that is limited to the clearly defined surgical pro-
cedure of left or right hepatectomy, was designed to
evaluate this matter.
Conventional resection methods such as the Finger
Fracture and the Clamp Crush techniques are challenged
by the use of several innovative parenchymal dissection
devices. Interestingly, a Cochrane database review of in-
novative and conventional liver resection techniques
from 2009 revealed the traditional Clamp Crush tech-
nique to provide comparable or lower BL at lowest cost
[11]. Traditionally, different modes of vascular occlusion
are applied to further limit blood loss in liver resection.
Total Hepatic Vascular Exclusion (THVE) includes the
temporary ligation or clamping of the portal triad with
simultaneous occlusion of the hepatic veins to prevent
retrograde hemorrhage during resection, whereas the
classic Pringle Maneuver (PM) only applies occlusion of
the arterial and portal inflow. Due to the relative ische-
mia tolerance of the liver, Intermittent Pringle Maneuver
(IPM) is utilized to facilitate extended resections with
limited BL. There is little evidence from well-designed
clinical trials to justify the widespread use of these tech-
niques. A meta-analysis from 2008 revealed no advan-
tage for the use of portal triad clamping in terms of
perioperative outcome [12]. Additionally, the innovation
of surgical techniques has led to a reduction in intraop-
erative BL, making inflow control dispensable. Through
the use of vascular staplers, the duration of parenchymal
resection has been significantly reduced to less than ten
minutes for major hepatic resections with excellent
safety [13, 14]. Nevertheless, a relevant blood loss still
occurs, even in anatomic resections. This might be at-
tributed to bleeding from the hepatic venous system, un-
controlled portoportal contralateral collaterals and
failing to follow the precise anatomical segemental
border during parenchyma dissection. Combining vascu-
lar occlusion techniques and stapler resection could help
to further minimize intraoperative BL. It is assumed that
the short duration of portal triad clamping has no nega-
tive impact on the perioperative outcome when applied
in stapler hepatectomy. Therefore, this RCT was de-
signed to evaluate the potential reduction of BL by the
combination of stapler hepatectomy and PM.
Objective
The trial’s objective is to test if PM reduces the intraop-
erative BL during left or right stapler hepatectomy. Fur-
thermore, perioperative outcome is analyzed to evaluate
the safety of the combination of PM and stapler resec-
tion technique.
Hypotheses
Null hypothesis: The intraoperative BL in both groups
does not differ to a clinically relevant extent with (H0):
BL 1 = BL 2.
Alternative hypothesis: The intraoperative BL in both
groups differs to a clinically relevant extent with (H1):
BL 1 ≠ BL 2.
Formal trial design
Single center prospective, randomized, controlled, paral-
lel, open, confirmatory trial.
Primary endpoint
 Total intraoperative BL during stapler hepatectomy
Definition and assessment: The entire BL from skin in-
cision to skin closure is defined as “intraoperative BL”.
For the assessment of the exact amount of hemorrhage
the volume of fluid in the suction container(s) that were
used during the procedure are recorded in the case re-
port form (CRF) by the end of the skin closure. Further-
more the numbers of all small and big surgical swabs are
recorded. All swabs together with the container that
catches dripping excess fluids underneath are weighed
by the end of skin closure and the exact weight in grams
is recorded in the CRF. The exact amount of rinse fluid
in milliliters that was used during the procedure is re-
corded in the CRF.
The calculation of total BL is as follows: The suction
container fluid volume (in milliliters) is added to the
weight (in grams) of all surgical swabs and the drip
catching container at the end of the skin closure (A).
The amount of ascites that may be suctioned from the
abdominal cavity initially is subtracted from that volume.
The difference of the density of the rinse solution (iso-
tonic sodium chloride solution) and blood is approxi-
mately 0.055 g/cm3. With regard to the exactness of the
measurements this difference is considered clinically
irrelevant.
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The volume of the entire rinse fluid (in milliliters) that
was used during the procedure is added to the known
dry weight (in grams) of the respective number of surgi-
cal swabs that were used during the procedure and the
known weight of the empty container they are weighed
in (B).
The total BL is defined as “A” minus “B” in milliliters.
Secondary endpoints
 Intraoperative BL per resection plane size (ml/cm2)
 Number of packed red blood cells (PRBC)
transfused intraoperatively
 Postoperative ALT levels day 1 and 3 (and their
relative delta)
 Postoperative total bilirubin levels day 1 and 3 (and
their relative delta)
 Postoperative INR day 1 and 3 (and its relative
delta)
 Number of PRBC transfused within the first three
postoperative days
 General surgical complications, classified according
to the “Clavien – Dindo” classification within the
first 30 postoperative days
 Mortality during the first ninety postoperative days
Tested method
All procedures are performed according to institutional
standards for liver surgery. Depending on the planned
procedure, an upper midline incision with or without
right lateral extension (“reversed L – shape”) is per-
formed in a regular dorsal position. After the hepatic le-
sion is confirmed to be treatable by resection, the liver is
freed from its ligaments and mobilized. In the treatment
group Classic PM is performed via silicon tube tourni-
quet of the portal triad just before the resection starts. If
the parenchymal resection exceeds fifteen minutes, the
tourniquet will be loosened for five minutes followed by
intermittent PM with five minute intervals of ischemia
and reperfusion until the parenchymal resection is fin-
ished. Liver resection itself is performed in the stapler
technique as described elsewhere [14]. Briefly, after iden-
tification of the resection plane, demarcation of the re-
section line by ligation of the specific hepatic arterial
and hepatic vein branches, the parenchyma is stepwise
fractured with a straight vascular clamp and dissected
with an Endo GIA vascular stapler (Medtronic, Endo
GIA™ Universal Roticulator 60–2.5 or Endo GIA™
Curved Tip 60mm Articulating Vascular/Medium Tri-
Staple™) in an alternating manner. After removal of the
resected specimen, pressure with a hot, wet surgical
swab is applied to the resection plane and PM is termi-
nated immediately thereafter by loosening of the tourni-
quet. In all cases the central venous pressure will be
kept at 5 mmHg or below by the anaesthesiologists
according to routine liver surgery standards in our
institution.
Risks of the tested method
Liver resection naturally carries the risk of bleeding, in-
dependent of the resection technique used. After PM
was first described as a means of haemorrhage control
in liver trauma [15], it has been applied by liver surgeons
to limit blood loss during elective liver resections. Poten-
tial harmful effects of PM have been widely discussed
over decades. Based on the work of Huguet from 1994 it
is widely accepted that warm ischemia due to PM is tol-
erated by healthy, non-cirrhotic livers for up to sixty mi-
nutes [16]. The parenchymal damage caused by ischemia
reperfusion is commonly monitored by measurement of
perioperative Liver transaminase levels. A meta-analysis
on the use of PM in 2008 showed no statistical differ-
ence in Transaminase levels when PM was compared to
hepatic resection without vascular occlusion [12]. Liver
cirrhosis is prevalent in many cases of hepatic resections,
especially for HCC. Based on experimental [17] and clin-
ical [18–20] data, cirrhotic livers are more sensitive to
ischemic damages including inflow occlusion. This effect
is believed to be strongly dependent on the duration of
the ischemic period. Accordingly, a clinical trial from
2004 found an advantage for intermittent portal clamp-
ing compared to continuous clamping in cirrhotic pa-
tients [21]. In this trial short ischemic periods of five
minutes, followed by five minutes of reperfusion repeti-
tively, were found to decrease the ischemia reperfusion
damage in cirrhotic livers indicated by blood tests.
PM has been proven to be applied safely for up to
sixty minutes in non-cirrhotic livers. By intermittent in-
flow occlusion the duration of resections under ischemia
could be extended to up to 120 min [22]. To prevent po-
tential harm in single cases with prolonged duration of
parenchymal resection, after fifteen minutes the tourni-
quet will be loosened for five minutes. In the following
intermittent PM with five-minute intervals of ischemia
and reperfusion will be applied until the parenchymal re-
section is finished. Considering the average duration of
parenchymal resection in this trial to be less than ten
minutes in total, no harmful effects are expected to be
caused by PM in the treatment group.
Inclusion criteria
– Patients undergoing open left or right hepatectomy
according to the Brisbane classification for benign or
malignant diseases)
– Age of eighteen years or older
– Written informed consent for participation in the
trial
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– Absence of a mental state preventing the subject to
understand the study related information
Exclusion criteria
– Situation post interventional or operative portal vein
embolization or ligation
– Anatomical alterations which render study treatment
impossible (e.g. a biliodigestive anastomosis, an
extraanatomic hepatic artery bypass, and/or any
other circumstance which renders PM or stapler
resection impossible)
– Simultaneous resection of other organs (excluding
the gall bladder and the common bile duct)
– Liver cirrhosis exceeding Child – Pugh score A
Patient selection
All patients who are scheduled for open left or right
hepatectomies are screened for participation in the trial
by a member of the Clinical Trial Center (KSC) of the
Department of Surgery, University Hospital Heidelberg.
Written informed consent is obtained from every subject
on the day before surgery the latest. Due to expected
drop outs because of intraoperative exclusion of
screened patients, approximately 155 patients will be
screened to include 106 patients in the final analysis.
Figure 1 gives an overview of the patients' course
through the trial. According to the above-mentioned in-
clusion and exclusion criteria subjects are randomized
equally to either of the two groups intraoperatively:
 Controls – liver resection applying standard stapler
parenchymal resection technique without hepatic
inflow control as described previously [14]
 Treatment group – liver resection applying standard
stapler parenchymal resection technique with
continuous PM (intermittent PM after fifteen
minutes of parenchymal resection)
Randomization
Randomization process
The randomization will facilitate numbered, opaque enve-
lopes, derived from a computer-generated random list by
a member of our institution who is not involved in the
trial otherwise. After the surgeon has performed the lapar-
otomy and verified that the resection can be performed as
planned without any impediments to the trial treatments,
the KSC will be informed. The allocation to the treatment
or control group in a 1:1 ratio will be done by a member
of the KSC by opening the respective envelope and imme-
diate informing of the operating team about the result.
The result of the randomization will be recorded in the
CRF. The stratification used for randomization is the type
of resection: left / right hepatectomy.
Data collection
Preoperatively, the patients´ general demographic and
medical data will be taken from the existing clinical
database (summarized in Table 1). According to the
study endpoints the following data will be recorded in-
traoperatively in the CRF:
 Intraoperative BL (as defined and described under
2.3.1)
 Resection plane surface in cm2 (obtained by printing
a standard DIN A 4, 1 × 1 cm checkered paper sheet
with the resected Liver; boxes on the edges of the
print < 50% coverage are neglected, boxes ≥50%
coverage are counted as one cm2)
 Duration of parenchymal resection in minutes
 Duration of PM in minutes (if intermittent PM is
applied, number and duration of occlusion periods)
 Type of resection (left or right hepatectomy
according to the Brisbane 2000 terminology)
 Time from skin incision to completion of skin
closure in minutes
 Number of PRBC transfused intraoperatively
 Protocol violations
To analyse inter-group comparability of differences in
the intraoperative BL, the central venous pressure (in
mmHg) during the resection is recorded.
Postoperatively, the following data will be recorded or
taken from the clinical database:
 Plasma ALT levels in U/L on postoperative day 1
and 3 (and their relative delta)
 Plasma Total bilirubin levels in mg/dl on
postoperative day 1 and 3 (and their relative
delta)
 INR on postoperative day 1 and 3 (and its relative
delta)
 Numbers of transfused PRBCs up to postoperative
day 3
 Incidence and type of a biliary leakage according to
the Koch classification within the first 30
postoperative days [23]
 General surgical complications, classified according
to the “Clavien-Dindo” classification within the first
30 postoperative days [24]
 Mortality up to day 90
 Duration of hospital stay
All generated data in the trial will be fully accessible to
the principal investigator PH exclusively.
Trial duration
Based on the sample size calculation (2.4.1), the evalu-
ation of the last patient will be completed (last patient
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out) 31 months after the start of screening for eligible
patients (first patient in). Another three months later the
results of the data analysis will be available. The individ-
ual duration of the trial for each patient is 91 days
(randomization on the day of surgery, follow up 90 days
postoperatively). Table 2 gives an overview of the trial
schedule according to the SPIRIT statement [25].
Termination of the trial
Individual criteria
If a patient withdraws his consent to participate in the
trial, no further data collection is done and all of his data
will be deleted upon demand. The patient will be asked
for the allowance to analyse the data that was collected
before the withdrawal of consent.
Termination of the entire trial
If new findings during the course of the trial reveal any
safety concerns regarding the investigated method, all
trial activity will be interrupted. If substantial safety con-
cerns remain, the entire trial will be terminated.
Scheduled termination of the trial is when at least 53
patients in both trial arms have completed the follow up.
Sample size
In our institution major liver resections are commonly
performed without PM. Based on the intraoperative
course, e.g. if extensive BL during parenchymal resection
occurs, PM is performed according to the surgeon’s ap-
praisal. In a retrospective analysis of 193 major liver re-
sections that were performed in our institution from
January 2011 until February 2014, we found a reduction
of the mean intraoperative BL of 27.4% (647 (+/− 612)
vs. 891 (+/− 783) ml) in the 62 cases with PM. Since PM
was only used when an extensive, uncommon BL was
detected, we expect the effect of PM to be substantially
higher among standard major liver resections in general.
Even though it is a generally accepted fact that blood
loss and PRBC transfusions during liver surgery nega-
tively affect patients’ outcome, it is uncertain if the effect
is straight proportional. In a recent work Wehry et al.
showed that the average amount of blood loss in 186
Table 1 Preoperatively recorded baseline data
General Age / gender / ASA status
General medical Previous abdominal surgery/previous hepatic surgery/chronic viral hepatitis/cirrhosis/blood coagulation disorders
Indication for resection Benign/primary malignant/secondary malignant / other
Preoperative blood results ALT/AST/total bilirubin/GGT/AP/INR/total albumin
ASA: American Society of Anaesthesiologists; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma glutamyl transferase; AP: alkaline
phosphatase; INR: international normalized ratio
Fig. 1 Trial Flowchart according to CONSORT
Houben et al. BMC Surgery           (2019) 19:60 Page 5 of 8
patients undergoing liver resection was reduced by ap-
proximately 400 ml if transfusions were not required
[10]. In this context it appears reasonable that this inter-
ventional trial should be designed powerful enough to
detect a reduction of blood loss of at least 400 ml. The
sample size calculation for this trial is therefore based
on the assumption that a reduction of the intraoperative
BL has to be at least 50% (a reduction of approximately
450 ml) to be clinically relevant. Therefore, 53 patients
have to be analyzed in each group to detect a 50% reduc-
tion of BL at a standard deviation of 94.1%, an alpha of
5% and an 80% power level. Assuming a realistic drop-
out rate due to intraoperative findings, contraindications
for major liver resection and other reasons 155 patients
are planned to be screened and asked for participation
in the trial.
Statistical methods
The non-parametric Mann-Whitney u test will be used
to compare the intraoperative BL values between both
treatment groups.
The Fisher’s exact test will be performed to compare
the rates of 30-day mortality, bile leakage, intraoperative
transfusion requirements, and blood transfusion require-
ments within the first three postoperative days between
both treatment groups.
Depending on the distribution of the quantitative pa-
rameters intraoperative BL per resection plane size, dur-
ation of surgical procedure, and duration of hospital stay
the T-test in case of a normal distributed parameter or
the non-parametric Mann-Whitney-U-Test will be used
to compare both treatment groups.
The postoperative ALT levels, total bilirubin levels,
and INR at day 1 and at day 3 will be compared between
both treatment groups using the T-test or the Mann-
Whitney-U-Test. The Bonferroni-Holm method will be
used to adjust the p-values.
Two-sided p-values < 0.05 will be considered as statis-
tically significant.
Safety/adverse events
Specification of adverse−/serious adverse events
“Adverse event” (AE) covers any sign, symptom, and
syndrome, that appears in a subject during the follow up
of the clinical trial and that may impair the well-being of
the subject.
AEs will be recorded on a special AE form in the CRF.
The following information will be recorded:
 Date of appearance
 Description of symptom
 Duration of AE
 Treatment
 Severity code: mild, moderate or severe
 Possible Relationship to trial treatment
 Outcome
Symptoms that are commonly seen after major liver
resections including postoperative pain, nausea and
vomiting, delay of bowel movement, fatigue and lack of
appetite will not be recorded as AE. AEs will be reported
to the principle investigator in regular intervals through-
out the study.
“Serious Adverse Event” (SAE) is any adverse event
that occurs at any time during the follow up period, that
results in death, is immediately life threatening, requires
hospital admission, results in persistent or significant
disability or incapacity or results in reoperation due to
any reason. SAEs will be documented on a special SAE
formula in the CRF and will be reported to the principle
Table 2 Trial visits schedule
Trial visits
Trial activity/examination Preoperatively Day of surgery POD 1 and 3 POD 30 POD 90
Screening, informed consent, preoperative baseline data (Table 1) X
Type of resection (left/right hepatectomy)/BL/resection plane surface
in cm2/number of transfused PRBC/duration of parenchymal resection/
duration of PM/central venous pressure during resection/time from
skin incision to completion of skin closure/protocol violations
X
ALT/AST/total bilirubin/GGT/AP/INR/total albumin/numbers of
transfused PRBCs/incidence of wound healing disorders/incidence
and type of biliary leakage
X
Incidence and type of wound healing disorders/incidence and type
of biliary leakage/duration of hospital stay/mortality
X
AE/SAE X X X
Mortality X
POD Postoperative day, BL blood loss, PRBC packed red blood cells, PM Pringle Maneuver, ALT alanine aminotransferase, INR international normalized ratio, AE
adverse event, SAE serious adverse event
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investigator within 24 h. The following information will
be recorded:
 Date of appearance
 Description of symptom
 Duration of SAE
 Treatment
 Severity code: mild, moderate or severe
 Possible relationship to trial treatment
 Outcome
SAEs which meet one of definitions of the secondary
endpoints are treated as SAEs regarding to documenta-
tion but have not to be reported to the sponsor/principle
investigator within 24 h. They will be reported to the
principle investigator in regular intervals throughout the
study.
Discussion
PriMal StHep is the first randomized clinical trial to test
the combination of PM and stapler resection technique
as a means to reduce intraoperative blood loss in hemi-
hepatectomies. The ongoing debate about potential
adverse effects of PM in major liver resection is mainly
attributed to extended durations of parenchymal dissec-
tion. As stapler hepatectomy has been proven to offer
safe time- and cost-effective parenchymal dissection, the
addition of PM to further reduce the intraoperative
blood loss appears promising.
Trail status
The PriMaL StHep trial has been prospectively regis-
tered to the German Clinical Trial Registry (WHO ID:
DRKS00010427) on April 21st, 2016.
The current protocol version is V. 1.5 from August
8th, 2017. The PriMaL StHep trial is recruiting since
June 2016. Recruitment will be completed approximately
in October 2018.
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